Don't want ads? Subscribe or login now.

Vaccine Developer Files Ch. 11 Sale Plan With $11.5M Bid

By Vince Sullivan · February 18, 2025, 6:13 PM EST

Omega Therapeutics, which develops mRNA vaccines, filed proposed bidding procedures in Delaware bankruptcy court, saying it hopes to get a sale approved by mid-April and has a stalking-horse bid in hand...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Bankruptcy Scorecard

Summary

Biotechnology company Omega Therapeutics hit Chapter 11 in Delaware, listing over $140 million of debt on its petition and having filed a form with the U.S. Securities and Exchange Commission saying it had entered a restructuring agreement with an affiliate of its controlling stockholder.

Case Number

1:25-bk-10211

Judge

Brendan L. Shannon

Venue

U.S. Bankruptcy Court for the Northern District of Alabama

Capital Structure

Total Liabilities:

Over $140.4 million in debt

View Full Scorecard

Documents

Motion